{"classes":[{"categories":[{"measurements":[{"comment":"An upper limit for the 95% Confidence Interval was unable to be reached for OS due to ongoing survival in some AML patients at the time of cutoff for data analysis (i.e., \\~21 months).","groupId":"OG000","lowerLimit":"11.3","upperLimit":"NA","value":"16.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"}],"units":"Participants"}],"description":"Median OS is reported in patients with AML at the time of censoring of data for the Primary Outcome analysis. For purposes of this study, OS refers to the duration of time from treatment initiation until a patient's death from any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Administration: Decitabine is reconstituted with 5 ml sterile water to facilitate subcutaneous administration. Decitabine is given by subcutaneous injection. Venetoclax is taken as a tablet prepared by patients pharmacy. Venetoclax is given at a dose of 400 mg po once per week concurrently with the Decitabine dose (+/- 1 day allowed ).\n\nVenetoclax: Venetoclax 400 mg po on days 1, 8, 15 and 22 of each cycle (28-day cycle)\n\nDecitabine: Decitabine 0.2 mg/kg SQ (subcutaneous) on days 2, 9, 16, 23 (for aggressive disease will add decitabine on days 3, 10, 17, 24)","id":"OG000","title":"Decitabine/Venetoclax (Single Arm)"}],"paramType":"MEDIAN","populationDescription":"21 patients who comprised the Primary Outcome analysis were part of the AML cohort.","reportingStatus":"POSTED","timeFrame":"At the time of censoring of data, up to ~21 months","title":"Overall Survival (OS) in AML Patients","type":"POST_HOC","unitOfMeasure":"months"}